AbbVie Talks Up Options In Drive For Diversification, But Humira Still Supreme
This article was originally published in The Pink Sheet Daily
Executive Summary
Biggest potential lies with the trio of oral antivirals filed at FDA to treat hepatitis C, but three Phase III cancer candidates may also play an important role in AbbVie’s future growth.